Kamiya Biomedical Company

KAMIYA BIOMEDICAL COMPANY was founded by Kohji Kamiya in March of 1983 in Thousand Oaks, California, with the purpose of supplying the life science and medical communities with innovative laboratory research and diagnostic tools of the highest quality. KAMIYA is an independent American company that serves worldwide markets. The companys first products were the cutting edge protein kinase inhibitors staurosporine and K252a for signal transduction research. In 1990, KAMIYA became the first company to introduce anti-Fas monoclonal antibodies to the U.S. research community. Since then, KAMIYA has become a leader in supplying quality apoptosis research products to the global market.  [ Click for details ]